Immunovant Beheer

Beheer criteriumcontroles 3/4

De CEO Immunovant is Pete Salzmann, benoemd in Dec2019, heeft een ambtstermijn van 4.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.55M, bestaande uit 8.2% salaris en 91.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde $ 13.48M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 4.9 jaar.

Belangrijke informatie

Pete Salzmann

Algemeen directeur

US$8.6m

Totale compensatie

Percentage CEO-salaris	8.2%
Dienstverband CEO	4.9yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Analyse CEO-vergoeding

Hoe is Pete Salzmann's beloning veranderd ten opzichte van Immunovant's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$323m
Jun 30 2024	n/a	n/a	-US$273m
Mar 31 2024	US$9m	US$700k	-US$259m
Dec 31 2023	n/a	n/a	-US$243m
Sep 30 2023	n/a	n/a	-US$255m
Jun 30 2023	n/a	n/a	-US$245m
Mar 31 2023	US$6m	US$625k	-US$211m
Dec 31 2022	n/a	n/a	-US$199m
Sep 30 2022	n/a	n/a	-US$177m
Jun 30 2022	n/a	n/a	-US$167m
Mar 31 2022	US$6m	US$600k	-US$157m
Dec 31 2021	n/a	n/a	-US$138m
Sep 30 2021	n/a	n/a	-US$128m
Jun 30 2021	n/a	n/a	-US$111m
Mar 31 2021	US$15m	US$567k	-US$107m
Dec 31 2020	n/a	n/a	-US$100m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$73m
Mar 31 2020	US$9m	US$361k	-US$66m

Compensatie versus markt: De totale vergoeding ($USD 8.55M ) Pete } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.59M ).

Compensatie versus inkomsten: De vergoeding van Pete is gestegen terwijl het bedrijf verliesgevend is.

CEO

Pete Salzmann (56 yo)

4.9yrs

Tenure

US$8,552,430

Compensatie

Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer and Director of Immunovant, Inc. since December 2019. Dr. Salzmann has served as a member of Immunovant Sciences Ltd.’s b...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Frank Torti	Executive Chairperson of the Board	4.9yrs	US$3.69m	0.014% $ 613.2k
Peter Salzmann	CEO & Director	4.9yrs	US$8.55m	0.30% $ 13.5m
Jay Stout	Chief Technology Officer	1.6yrs	US$4.04m	geen gegevens
Eva Barnett	Chief Financial Officer	3.1yrs	US$2.07m	0.091% $ 4.1m
Mark Levine	Chief Legal Officer & Corporate Secretary	2.8yrs	geen gegevens	0.076% $ 3.4m
Lauren Schrier	Vice President of Marketing	4.8yrs	geen gegevens	geen gegevens
Christine Blodgett	Senior Vice President of Human Resources	no data	geen gegevens	geen gegevens
William Macias	Chief Medical Officer	3.4yrs	US$1.92m	0.13% $ 6.0m
Andy Deig	Senior Vice President of Strategic Finance	no data	geen gegevens	geen gegevens
Michael Geffner	Chief Medical Officer	less than a year	geen gegevens	0.016% $ 727.9k
Julie Kirschling	Senior Vice President of Program & Alliance Management	no data	geen gegevens	geen gegevens
Jody Roth	Senior Vice President of Regulatory Affairs	no data	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IMVT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Frank Torti	Executive Chairperson of the Board	4.9yrs	US$3.69m	0.014% $ 613.2k
Peter Salzmann	CEO & Director	4.9yrs	US$8.55m	0.30% $ 13.5m
George Migausky	Independent Director	4.9yrs	US$291.32k	0.027% $ 1.2m
Andrew Fromkin	Director	5.1yrs	US$445.00k	0.012% $ 547.1k
Atul Pande	Independent Director	5.1yrs	US$287.62k	0.022% $ 991.6k
Douglas Hughes	Independent Director	4.9yrs	US$436.30k	0.012% $ 559.2k
Eric Venker	Director	4.8yrs	US$55.00k	geen gegevens

4.9yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IMVT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Immunovant Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

CEO & Director recently sold US$480k worth of stock

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

CEO & Director recently sold US$486k worth of stock

Recent updates

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Price target decreased to US$10.78

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Price target decreased to US$11.25

Chief Medical Officer recently sold US$222k worth of stock

Price target decreased to US$12.25

Immunovant, Inc. Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Independent Director recently bought US$150k worth of stock

Independent Director recently bought US$54k worth of stock

Price target decreased to US$19.86

Immunovant, Inc. announced that it has received $199.999993 million in funding